# National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)

> **NIH NIH U24** · INDIANA UNIVERSITY INDIANAPOLIS · 2022 · $396,250

## Abstract

ABSTRACT
The US National Plan for AD (National Alzheimer's Project Act, NAPA) has the ambitious goal of
preventing and effectively treating Alzheimer’s disease (AD) by 2025 through the support of
innovative research focused on AD etiology, early detection, and therapeutics. The National
Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) is an NIA-
funded Cooperative Agreement that serves as the primary resource for sample sharing for all
NIA-funded Alzheimer’s disease and related dementias (ADRD) studies. Throughout the
remainder of the grant, NCRAD will work closely with NIA and other national efforts in ADRD
research to advance genomic and biomarker efforts aimed at identifying those at greatest risk for
ADRD and to delay and prevent ADRD.
With the rapid development of blood-based biomarkers, there is an urgency to have a central
laboratory in the United States that can process large numbers of samples in a standardized
manner and return the data to studies. To meet this goal, Indiana University School of Medicine
is establishing a new biomarker laboratory that will produce key plasma assays for samples
banked at NCRAD. NCRAD will limit its focus to biomarkers that are well established and can be
implemented as commercial assays. Initial assays will be: P-tau181, NfL, Aβ1-40 and Aβ1-42
NCRAD’s approach will ensure that standardization of processes and delivery of reliable and
consistent research biomarker results can be achieved. It will also allow for longitudinal quality
monitoring and consistent delivery of results over time as well as the opportunity for cross-
laboratory comparability studies. There are several key advantages to centralizing the biomarker
laboratory at NCRAD. First, NCRAD is a trusted partner to ADRD studies. Second, since NCRAD
banks samples from over 45 studies, integrating the biomarker laboratory within NCRAD is a
seamless process to return assay data to the contributing study. Third, studies without a
biomarker focus can easily partner with NCRAD to include plasma biomarkers with minimal effort.
This administrative supplement provides the funds for NCRAD to support the laboratory staff
essential for the biomarker laboratory.

## Key facts

- **NIH application ID:** 10509812
- **Project number:** 3U24AG021886-20S2
- **Recipient organization:** INDIANA UNIVERSITY INDIANAPOLIS
- **Principal Investigator:** TATIANA M. FOROUD
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $396,250
- **Award type:** 3
- **Project period:** 2002-07-15 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10509812

## Citation

> US National Institutes of Health, RePORTER application 10509812, National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) (3U24AG021886-20S2). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10509812. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*